U-Factor Announces 'Excellence Award' for ALS Research by Partner Hitonowa Medical Clinic at the 24th Congress of the Japanese Society for Regenerative Medicine
TOKYO--(BUSINESS WIRE)--U-Factor Co., Ltd. ('U-Factor') is pleased to announce that partner Hitonowa Medical Clinic has received the 'Excellence Award' at the 24th Congress of the Japanese Society for Regenerative Medicine for pioneering research on amyotrophic lateral sclerosis (ALS). This milestone in regenerative medicine provides strong momentum for both organizations' joint research and business development.
Research Overview
Background: A retrospective cohort study was conducted from January 2022 to November 2023, involving 24 ALS patients.
Treatment Method: Conditioned media derived from stem cells of human exfoliated deciduous teeth (SHED-CM) was administered to verify safety and effectiveness.
Key Findings: The ALS Functional Rating Scale–Revised (ALSFRS-R) decline was slower than anticipated. Some patients experienced symptom improvement, including restored leg movement (see reference video).
Safety: Only 3% of patients reported mild adverse events. No severe allergic reactions or clinically significant laboratory abnormalities were observed.
Conclusion: SHED-CM may be safe and promising for ALS, raising expectations for further clinical development.
These findings have also been published in Biomedicines (MDPI, 2023, 12(10), 2193), garnering attention in regenerative medicine.
Significance of the Award and Future Outlook
This award reflects U-Factor's cutting-edge regenerative technologies and Hitonowa Medical Clinic's clinical approach to intractable diseases. U-Factor will continue strengthening its collaboration with Hitonowa, accelerating global clinical trials and regulatory approvals. As of April 2025, they are jointly conducting a specified clinical study (jRCT031230731) for ALS.
https://u-factor.com/en/news/als
About U-Factor Co., Ltd.
Established in 2020, U-Factor is a regenerative medicine biotech company focused on SHED-CM research and development. Through partnerships with medical and academic institutions, it delivers safe, effective, and scalable regenerative solutions globally.
https://u-factor.com/en/
About Hitonowa Medical Clinic
Hitonowa Medical Clinic is founded on the principle of 'regenerative medicine × intractable diseases,' providing patient-centered care by supporting patients and confronting conditions together. Since 2020, it has used stem cell culture supernatant to treat ALS—one of the most difficult-to-treat diseases—along with stroke and dementia. By harnessing regenerative technologies, Hitonowa unites patients, families, and healthcare providers to face these conditions.
https://hitonowa-medical.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Panasonic Professional Video & Audio Systems Names Caroline Niedzwiecki as Director of Sales
NEWARK, N.J.--(BUSINESS WIRE)--Panasonic Entertainment & Communication Co., Ltd. today announced that Caroline Niedzwiecki has been appointed as director of sales. In this role, Caroline will oversee the company's audio and video business, which includes Panasonic's suite of Pan-Tilt-Zoom (PTZ), studio, and box cameras, camcorder portfolio, media production and audio solutions, and the KAIROS Live Video Production Platform. "The company's mission resonates with my passion for leveraging technology to deliver meaningful experiences. I'm excited to work with Panasonic's high-performing sales team." Niedzwiecki brings more than 25 years of experience in the professional AV and M&E industry, with a strong background in business development and sales leadership. She most recently served as the general manager and vice president at disguise where she spent three years leading the company's North and South American sales. Prior to disguise, she was the vice president of global sales at BirdDog and senior vice president of business development at NewTek (now a Vizrt company) where she spent nearly a decade leading their sales expansion in North America, EMEA, and the successful launch of NDI products globally. She also held positions at Avid Technology Inc. and was a member of SVGW (formerly Women's Sports Media Initiative), an organization focused on enhancing the role of women in the creation, production and distribution of sports content. 'Panasonic's commitment to delivering glass-to-glass solutions allows its customers to fundamentally enhance the way people work, live, and experience live events,' said Caroline Niedzwiecki, Director of Sales, Panasonic Professional Video & Audio Systems. 'The company's mission resonates with my passion for leveraging technology to deliver meaningful experiences. I'm excited to work with Panasonic's high-performing sales team as the broadcast industry continues to undergo rapid transformation and becomes more reliant on scalable, interoperable technology to meet consumer demands.' As director of sales, Niedzwiecki will maintain, grow, and build new relationships with customers and partners across corporate, higher education, house of worship, broadcast, sports, and live events. Her deep knowledge of the audiovisual industry allows her to lead high-performing teams with a clear purpose that keeps them focused on delivering tailored solutions to meet each customer's unique needs. With the professional AV market experiencing rapid growth, Niedzwiecki is committed to driving long-term growth for Panasonic and helping its customers understand the value of investing in unified communications. About Panasonic Entertainment & Communication Co., Ltd. Panasonic Entertainment & Communication Co., Ltd. established in April 2022 as part of the Panasonic Group's switch to an operating company system, is strengthening the bonds among people and enriching our customers' lives by providing consumer electronics, including AVC products such as OLED TVs, Lumix digital cameras, headphones, phones, intercoms, and more, as well as business products and solutions including for broadcast, professional AV, and sound systems globally. Our mission is to offer people new emotion and relaxation through our entertainment and communication solutions. To fulfill this mission, we strive to act with professionalism to continuously recreate the future by connecting people. For more details, please visit
Yahoo
11 hours ago
- Yahoo
Taking A Look At ALS Limited's (ASX:ALQ) ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we'll use ROE to better understand ALS Limited (ASX:ALQ). Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for ALS is: 20% = AU$259m ÷ AU$1.3b (Based on the trailing twelve months to March 2025). The 'return' is the income the business earned over the last year. That means that for every A$1 worth of shareholders' equity, the company generated A$0.20 in profit. View our latest analysis for ALS By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. If you look at the image below, you can see ALS has a similar ROE to the average in the Professional Services industry classification (20%). That's neither particularly good, nor bad. While at least the ROE is not lower than the industry, its still worth checking what role the company's debt plays as high debt levels relative to equity may also make the ROE appear high. If a company takes on too much debt, it is at higher risk of defaulting on interest payments. Virtually all companies need money to invest in the business, to grow profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same. ALS does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.31. While its ROE is pretty respectable, the amount of debt the company is carrying currently is not ideal. Investors should think carefully about how a company might perform if it was unable to borrow so easily, because credit markets do change over time. Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. All else being equal, a higher ROE is better. But when a business is high quality, the market often bids it up to a price that reflects this. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So I think it may be worth checking this free report on analyst forecasts for the company. But note: ALS may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Taking A Look At ALS Limited's (ASX:ALQ) ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we'll use ROE to better understand ALS Limited (ASX:ALQ). Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for ALS is: 20% = AU$259m ÷ AU$1.3b (Based on the trailing twelve months to March 2025). The 'return' is the income the business earned over the last year. That means that for every A$1 worth of shareholders' equity, the company generated A$0.20 in profit. View our latest analysis for ALS By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. If you look at the image below, you can see ALS has a similar ROE to the average in the Professional Services industry classification (20%). That's neither particularly good, nor bad. While at least the ROE is not lower than the industry, its still worth checking what role the company's debt plays as high debt levels relative to equity may also make the ROE appear high. If a company takes on too much debt, it is at higher risk of defaulting on interest payments. Virtually all companies need money to invest in the business, to grow profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same. ALS does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.31. While its ROE is pretty respectable, the amount of debt the company is carrying currently is not ideal. Investors should think carefully about how a company might perform if it was unable to borrow so easily, because credit markets do change over time. Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. All else being equal, a higher ROE is better. But when a business is high quality, the market often bids it up to a price that reflects this. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So I think it may be worth checking this free report on analyst forecasts for the company. But note: ALS may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
